Gladstone scientists reprogram skin cells into insulin-producing pancreas cells
A cure for type 1 diabetes has long eluded even the top experts. Not because they do not know what must be done—but because the tools did not exist to do it. But now scientists in the laboratory of Gladstone Institutes’ Investigator Sheng Ding, MD, PhD, harnessing the power of regenerative medicine, have developed a technique in animal models that could replenish the very cells destroyed by the disease. The team’s findings, published online today in the journal Cell Stem Cell, are an important step towards freeing patients from the life-long injections that characterize this devastating disease.
Type 1 diabetes, which usually manifests during childhood, is caused by the destruction of beta-cells (?-cells). ?-cells are a type of cell that normally resides in the pancreas and produces a hormone called insulin. Without insulin, the body’s organs have difficulty absorbing sugars, such as glucose, from the blood. Once a death sentence, the disease can now be managed with regular glucose monitoring and insulin injections. A more permanent solution, however, would be to replace the missing ?-cells. But these cells are hard to come by, so researchers have looked towards stem cell technology as a way to make them.
“The power of regenerative medicine is that it can potentially provide an unlimited source of functional, insulin-producing ?-cells that can then be transplanted into the patient,” said Dr. Ding. “But previous attempts to produce large quantities of healthy ?-cells—and to develop a workable delivery system—have not been entirely successful. So we took a somewhat different approach.”
One of the major challenges to generating large quantities of ?-cells is that these cells have limited regenerative ability; once they mature it’s difficult to make more. So the team decided to go one step backwards in the life cycle of the cell.
The team first collected skin cells, called fibroblasts, from laboratory mice. Then, by treating the fibroblasts with a unique ‘cocktail’ of molecules and reprogramming factors, they transformed the cells into endoderm-like cells. Endoderm cells are a type of cell found in the early embryo, and which eventually mature into the body’s major organs—including the pancreas, the home of ?-cells.
“Using another chemical cocktail, we then transformed these endoderm-like cells into cells that mimicked early pancreas-like cells, which we called PPLC’s,” said Gladstone Postdoctoral Scholar Ke Li, PhD, the paper’s lead author. “Our initial goal was to see whether we could coax these PPLC’s to mature into cells that, like ?-cells, respond to the correct chemical signals and—most importantly—secrete insulin. And our initial experiments, performed in a petri dish, revealed that they did.”
The research team then wanted to see whether the same would occur in live animal models. So they transplanted PPLC’s into mice modified to have hyperglycemia (high glucose levels), a key indicator of diabetes.
“Importantly, just one week post-transplant, the animals’ glucose levels started to decrease, and gradually approached normal levels,” continued Dr. Li. “And when we removed the transplanted cells, we saw an immediate glucose spike, revealing a direct link between the transplantation of the PPLC’s and reduced hyperglycemia.”
But it was when the team tested the mice eight weeks post-transplant that they saw more dramatic changes: the PPLC’s had given rise to functional, insulin-secreting ?-cells.
“These results not only highlight the power of small molecules in cellular reprogramming, and are proof-of-principle that could one day be used as a personalized therapeutic approach in patients,” explained Dr. Ding.
The Latest on: Type 1 Diabetes
via Google News
The Latest on: Type 1 Diabetes
- Global Type 2 Diabetes Market - Expected Increase in the Diagnosed Prevalent Cases of T2D to 212,237,385 by 2028 - ResearchAndMarkets.comon March 24, 2020 at 7:59 am
T2D constitutes approximately 90-95% of all diabetes cases around the world, while type 1 diabetes (T1D) and gestational diabetes make up the remaining 5-10% of the cases (International Diabetes ...
- miR-216a-targeting theranostic nanoparticles promote proliferation of insulin-secreting cells in type 1 diabetes animal modelon March 24, 2020 at 3:20 am
Loss of beta cell mass and function underlies the pathology of both type 1 and type 2 diabetes 9. As pancreatic beta cells play a central role in the disease progression, anti-diabetic therapies ...
- FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabeteson March 23, 2020 at 3:26 pm
A type 2 diabetes drug marketed by Boehringer Ingelheim and Eli Lilly has fallen short of a bid to expand the medicine’s approval to patients who have type 1 diabetes. Type 1 diabetes is an autoimmune ...
- Stream your walk: Fundraiser to fight type 1 diabetes is going virtualon March 23, 2020 at 12:58 pm
Stream your walk: Fundraiser to fight type 1 diabetes is going virtual JDRF, like many great causes, depend on their annual charity drive to garner donations in order to help fulfill their mission of ...
- FDA rejects lower-dose empagliflozin 2.5 mg for type 1 diabeteson March 20, 2020 at 3:01 pm
The FDA on Friday issued a complete response letter for a supplemental new drug application for a 2.5 mg dose of the SGLT2 inhibitor empagliflozin as an adjunct to insulin for adults with type 1 ...
- Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012on March 20, 2020 at 10:32 am
Diagnoses of type 1 and type 2 diabetes in youths present a substantial clinical and public health burden. The prevalence of these diseases increased in the 2001–2009 period, but data on recent ...
- Study Identifies Two Distinct Type 1 Diabetes 'Endotypes'on March 18, 2020 at 6:47 am
Two histologically distinct "endotypes" of type 1 diabetes, T1DE1 and T1DE2, have been identified in children based on their age at diagnosis. The findings were published online March 15 in ...
- Type 1 Diabetes Looks Like It's Actually 2 Separate Diseases, Scientists Findon March 17, 2020 at 1:17 am
Diabetes has afflicted humanity for thousands of years, but despite it being an old burden, we're still making major discoveries about how the illness actually manifests, as new research shows. The ...
- Type 1 diabetes may be two conditions that need different treatmentson March 16, 2020 at 5:07 pm
Diabetes is generally thought to come in two forms: type 1 and type 2. But a study suggests type 1 diabetes could be two separate conditions, meaning there are more forms than we realised. People with ...
- Type 1 diabetes mellitus comprises of two different conditions based on ageon March 16, 2020 at 8:13 am
A new study published in the journal Diabetologia in March 2020 reports that children aged below seven years with type 1 diabetes mellitus (T1DM) have a distinct form of the condition from children ...
via Bing News